Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.

Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, Kamphaus GD, Fraley C, Zhang Y, Dumont JA, Bitonti AJ.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2337-42. doi: 10.1073/pnas.0708960105. Epub 2008 Feb 12.

2.

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.

Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A.

MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353.

3.

Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction.

Mezo AR, McDonnell KA, Castro A, Fraley C.

Bioorg Med Chem. 2008 Jun 15;16(12):6394-405. doi: 10.1016/j.bmc.2008.05.004. Epub 2008 May 6.

PMID:
18501614
4.

Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.

Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V.

J Immunol Methods. 2013 Apr 30;390(1-2):81-91. doi: 10.1016/j.jim.2013.01.011. Epub 2013 Feb 4.

PMID:
23384837
5.

Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction.

Wang Z, Fraley C, Mezo AR.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1253-6. doi: 10.1016/j.bmcl.2013.01.014. Epub 2013 Jan 11.

PMID:
23375228
6.

Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.

Wang Y, Tian Z, Thirumalai D, Zhang X.

J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. Review.

PMID:
24404896
7.

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB.

J Immunol. 2009 Jun 15;182(12):7663-71. doi: 10.4049/jimmunol.0804182.

8.

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC.

Int Immunol. 2006 Dec;18(12):1759-69. Epub 2006 Oct 31.

PMID:
17077181
9.

A strategy for bacterial production of a soluble functional human neonatal Fc receptor.

Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I.

J Immunol Methods. 2008 Feb 29;331(1-2):39-49. Epub 2007 Dec 10.

PMID:
18155020
10.

Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.

Kliwinski C, Cooper PR, Perkinson R, Mabus JR, Tam SH, Wilkinson TM, Giles-Komar J, Scallon B, Powers GD, Hornby PJ.

Am J Physiol Gastrointest Liver Physiol. 2013 Feb 1;304(3):G262-70. doi: 10.1152/ajpgi.00340.2012. Epub 2012 Dec 6.

11.

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, Koch S, Papadimitriou A.

MAbs. 2013 Jul-Aug;5(4):576-86. doi: 10.4161/mabs.24981. Epub 2013 May 29.

12.

Characterization and screening of IgG binding to the neonatal Fc receptor.

Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, Tiller T, Brocks B, Ostendorp R, Pabst S.

MAbs. 2014 Jul-Aug;6(4):928-42. doi: 10.4161/mabs.28744. Epub 2014 Apr 7.

13.

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T.

J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18.

14.
15.

Neonatal Fc receptor and IgG-based therapeutics.

Kuo TT, Aveson VG.

MAbs. 2011 Sep-Oct;3(5):422-30. doi: 10.4161/mabs.3.5.16983. Epub 2011 Sep 1. Review.

16.

X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.

Mezo AR, Sridhar V, Badger J, Sakorafas P, Nienaber V.

J Biol Chem. 2010 Sep 3;285(36):27694-701. doi: 10.1074/jbc.M110.120667. Epub 2010 Jun 30.

17.

Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.

Pollastrini J, Dillon TM, Bondarenko P, Chou RY.

Anal Biochem. 2011 Jul 1;414(1):88-98. doi: 10.1016/j.ab.2011.03.001. Epub 2011 Mar 6.

PMID:
21385563
18.

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.

Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ.

J Biol Chem. 2007 Jan 19;282(3):1709-17. Epub 2006 Nov 29.

19.

Albumin binding to FcRn: distinct from the FcRn-IgG interaction.

Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL.

Biochemistry. 2006 Apr 18;45(15):4983-90.

PMID:
16605266
20.

Supplemental Content

Support Center